The Life Sciences team advised Fate Therapeutics on the closing of its public offering of 10,648,149 shares of its common stock, which included 1,388,889 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $13.50 per share. The gross proceeds were approximately $143.8 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.
The Goodwin team was led by partner Maggie Wong and included partners Kingsley Taft, Janet Andolina, Bradley Bugdanowitz; counsel Stephanie Philbin; and associates Natalie Martirossian and Andrew Wilson.
For additional details on the offering, please read the press release.